EV-SOX9 Extracellular Vesicles for Cartilage Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cartilage damage, particularly osteoarthritis, are inadequate as they only provide temporary relief or regeneration of fibrocartilage instead of hyaline cartilage, and cannot completely prevent progressive joint destruction.
Innovation Solution
The use of SOX9 mRNA encapsulated in extracellular vesicles (EV-SOX9) to promote chondrogenic induction and cartilage repair by administering a therapeutically effective amount of EV-SOX9, which can be derived from mesenchymal stem cells, to enhance cartilage regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional treatments (analgesics, steroids, non-steroidal anti-inflammatory drugs) are used, then pain relief and anti-inflammatory effect are achieved, but cartilage regeneration is not promoted and joint destruction continues progressively
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers to deliver SOX9 mRNA to cartilage cells. These EVs serve as a mediator between the administered therapy and the target cells, enabling gene transfer without direct cell contact or integration, thus achieving cartilage regeneration while managing the harmful effects of OA
Solution Approach 2:
The patent changes the molecular parameter by introducing and overexpressing SOX9 mRNA in cartilage cells through EV delivery. This parameter change (increased SOX9 expression) transforms the cellular state to promote chondrogenesis and cartilage matrix production, fundamentally altering the treatment outcome from symptom relief to tissue regeneration
2Duration of action of stationary object
If cartilage protectants (hyaluronic acid, glucosamine, chondroitin) are used, then temporary protection and nourishment of cartilage cells are achieved, but complete cartilage regeneration and prevention of progressive joint destruction are not realized
Solution Approach 1:
The patent performs preliminary action by pre-packaging SOX9 mRNA within extracellular vesicles before administration. This pre-prepared EV-SOX9 complex is delivered directly to the cartilage damage site, where it immediately begins promoting chondrogenesis and cartilage matrix synthesis, achieving complete regeneration rather than temporary protection
Solution Approach 2:
The patent uses extracellular vesicles as copying carriers that can be generated from various cell sources (mesenchymal stem cells, synoviocytes, etc.). These EV copies contain the therapeutic SOX9 mRNA and can be administered without using the original cell source directly, enabling complete cartilage regeneration through molecular copying rather than temporary protective effects
3Reliability
If bone marrow stimulation with stem cells is performed, then cartilage regeneration is attempted, but fibrocartilage is regenerated instead of hyaline cartilage and the procedure is invasive
Solution Approach 1:
The patent replaces the mechanical invasive procedure of bone marrow stimulation with a molecular approach using EV-delivered SOX9 mRNA. Instead of mechanically extracting and injecting stem cells into the joint, the therapy uses non-invasive EV injection that delivers genetic material to promote hyaline cartilage regeneration, eliminating the need for invasive surgery while achieving superior cartilage quality
Solution Approach 2:
The patent changes the regenerative parameter by specifically targeting SOX9 gene expression to promote hyaline cartilage formation rather than general stem cell proliferation. This molecular parameter change (SOX9 overexpression) ensures hyaline cartilage regeneration instead of fibrocartilage, avoiding the need for invasive bone marrow stimulation procedures
4Reliability
If osteochondral graft is performed, then cartilage tissue is transplanted to damage site, but it cannot be used for large damage sites and requires collecting tissue from other body parts
Solution Approach 1:
The patent achieves universality by using extracellular vesicles as a versatile delivery platform that can be generated from multiple cell sources (mesenchymal stem cells, synoviocytes, fibroblasts) and administered to various cartilage damage locations and sizes. This multi-functional EV-SOX9 therapy can treat both small and large damage sites without requiring tissue collection from specific donor sites, overcoming the limitations of osteochondral grafting
Data Source
AI summary
The present invention is related to a method and pharmaceutical composition for treating a cartilage damage in a subject (including a human or an animal), particularly osteoarthritis (OA), using extracellular vesicles (EVs) with SOX9 gene, called as “EV-SOX9”. The EV-SOX9 is obtained by encapsulating the SOX9 mRNA or the mRNA of its upstream and downstream gene in EVs, naïve EVs with high expression level of SOX9 mRNA or its upstream and downstream gene from different cell sources, or MSC-derived EV-SOX9, which is obtained by transferring the SOX9 gene or its upstream and downstream gene into a multipotent cell and collecting EVs.